Eaton Vance Management’s 10x Genomics TXG Stock Holding History

Eaton Vance Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$14.3M	Sell	501,952 -242,322	-33%	-$9.23M	0.02%	516
2022 Q2	$33.7M	Buy	744,274 +61,411	+9%	+$3.19M	0.05%	348
2022 Q1	$51.9M	Sell	682,863 -32,718	-5%	-$2.86M	0.06%	298
2021 Q4	$107M	Sell	715,581 -17,666	-2%	-$2.71M	0.13%	154
2021 Q3	$107M	Buy	733,247 +8,578	+1%	+$1.47M	0.15%	141
2021 Q2	$142M	Buy	724,669 +232,488	+47%	+$42.1M	0.19%	115
2021 Q1	$89.1M	Buy	492,181 +221,396	+82%	+$38.2M	0.13%	164
2020 Q4	$38.3M	Sell	270,785 -22,830	-8%	-$3.31M	0.06%	294
2020 Q3	$36.6M	Buy	293,615 +27,412	+10%	+$2.88M	0.07%	259
2020 Q2	$23.8M	Buy	266,203 +16,122	+6%	+$1.26M	0.05%	309
2020 Q1	$15.6M	Buy	250,081 +162,308	+185%	+$12.7M	0.04%	333
2019 Q4	$6.69M	Buy	87,773 +60,333	+220%	+$3.63M	0.01%	542
2019 Q3	$1.38M	Buy	+27,440	New	+$1.52M	﹤0.01%	886

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eaton Vance Management's TXG Position: Q3 2022 in Review

Eaton Vance Management reduced its 10x Genomics (TXG) stake by 33% in Q3 2022, selling an estimated $9.23M and leaving 501,952 shares worth $14.3M. The position accounts for 0.02% of the portfolio, ranked #516.

Eaton Vance Management first reported a position in TXG in Q3 2019 and has held it in 13 quarters since. The position peaked at $142M in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

Eaton Vance Management held 501,952 shares of 10x Genomics worth $14.3M as of Q3 2022.
Eaton Vance Management sold 242,322 10x Genomics shares in Q3 2022, an estimated $9.23M.
10x Genomics made up 0.02% of Eaton Vance Management's portfolio in Q3 2022, its #516 holding.
Eaton Vance Management first reported a position in 10x Genomics in Q3 2019 and has held it in 13 quarters since.
Eaton Vance Management's 10x Genomics position peaked at $142M in Q2 2021.
233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.